HeartGenetics is proud to announce Pronacera Therapeutics as the first Spanish partner. Pronacera, a spin-off from the the University Pablo Olavide, Sevilla, was estabilished in 2011 with the aim of improving patients’ quality of life through the development and lab-to-clinic transfer of biotechnological treatments. Extracorporeal Photopheresis (ECP) for immune disorders, efficacy testing of FDA approved drugs using patients’ fibroblasts, and detection of mitochondrial mutations are among available services. The company also holds two patents, one for apoptotic cells stabilizers and another for a screening and/or evaluation method of drug effectiveness in the treatment of mitochondrial diseases and MELAS syndrome.
Pronacera’s personalised medicine services have been further expanded as the company now offers cardiovascular genetic testing, provided by HeartGenetics.
This article was published on May 9, 2016.